US finalizes 2.48% Medicare Advantage payment hike; insurance stocks surge

CMS finalized a 2.48% average increase to 2027 Medicare Advantage payments, which CMS said will result in more than $13 billion of additional payments to plans in 2027. UnitedHealth, CVS and Humana shares rose 8–14% in extended trading as the final rate reverses the much smaller 0.09% January proposal and should provide relief to insurers (2026 final rate had been 5.06% after an initial 2.2% proposal).

Analysis

The change in CMS posture materially reallocates downside risk across the MA ecosystem: plans with concentrated MA exposure will see earnings visibility improve faster than vertically diversified competitors, compressing implied risk premia in their equity valuations over the next 6–12 months. Expect analysts to raise FY27 EPS and roll forward multiple expansion for higher-beta MA names, but much of that re-rating will be gated by enrollment trends and HCC risk-adjustment updates.

Second-order winners include PBM and care-management businesses that capture a higher share of incremental MA margin through utilization management and negotiated network rates; conversely, high-cost provider systems and SNF operators face renewed pressure to accept narrower in-network economics or risk volume declines. The capital market effect: regional insurers with scale but limited PBM capabilities become takeover targets as buyers seek to buy MA flow and operational levers cheaply.

Key risks that can reverse the move are retroactive adjustments from risk-score audits, faster-than-expected medical-cost inflation, or a regulatory pivot under a different administration — any of which would compress forward earnings estimates within quarters. Operational catalysts to watch are AEP enrollment momentum (next 6 months), CMS guidance on risk-adjustment/audit timelines, and company-level reserve revisions that will show up in seasonal filings and conference calls.

Key Decisions for Investors

• Long HUM (6–12 month): buy HUM equity or a call-spread (buy calls and finance with shorter-dated calls) sized 3–5% of book to capture the highest operating leverage to MA flows. Target +35–50% from entry on positive AEP enrollment and FY27 guide upgrades; hard stop -15% on downside or if CMS signals retroactive clawbacks.
• Pair trade — long HUM / short UNH (6–9 month, net neutral dollar): overweight HUM by 1.5x and short UNH to neutralize broader market beta and PBM exposure. This isolates MA concentration upside; target relative outperformance of 20–30% and limit relative drawdown to 10%.
• Buy UNH on weakness (3–12 month): accumulate UNH on pullbacks below key technical/support levels using a conservative put hedge or buy-write to compress cost basis. Expect lower upside but higher downside protection; target total return 15–25% with max downside risk defined by hedge cost.
• Event-monitor and hedge: set alerts for CMS risk-adjustment/audit announcements and mid-AEP enrollment data; if adverse headlines appear, hedge MA exposure by buying short-dated puts on HUM/CVS sized to 50–75% of directional positions.